Abstract
ATMPs are medicines for human use that can be classified into gene therapy, somatic-cell therapy and tissue-engineered medicines. If these are medicines with new active substances, ATMPs have to undergo a benefit assessment according to §35a Social Code Book (SGB) V. The objective of this analysis was to determine if ATMPs have the same Health Technology Assessment (HTA) requirements as other drugs in Germany.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
